Collecting and Storing Tissue From Young Patients With Cancer
- Conditions
- Ewing SarcomaRetinoblastomaCentral Nervous System NeoplasmGerm Cell TumorLeukemiaLymphomaRhabdoid TumorRhabdomyosarcomaAcute Lymphoblastic LeukemiaMalignant Neoplasm
- Interventions
- Other: Cytology Specimen Collection ProcedureOther: Laboratory Biomarker Analysis
- Registration Number
- NCT00898755
- Lead Sponsor
- Children's Oncology Group
- Brief Summary
This laboratory study is collecting and storing tissue, blood, and bone marrow samples from young patients with cancer. Collecting and storing samples of tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Detailed Description
PRIMARY OBJECTIVES:
I. Establish and bank cell lines and/or xenografts from pediatric patients with cancer.
II. Establish continuous cell lines, under carefully controlled conditions, from pediatric patients with cancer.
III. Establish transplantable xenografts in immunocompromised mice from tumor cells that are difficult to establish as continuous cell lines in vitro.
IV. Create a bank of cell lines and generate sufficient vials of cryopreserved cells for distribution to investigators with approved COG biology protocols. V. Characterize cell lines from childhood cancers with respect to DNA short tandem repeat molecular profile as a "fingerprint" of original cell line identity.
VI. Characterize cell lines for the ability for sustained growth in tissue culture and/or as mouse xenografts.
VII. Characterize cell lines for mycoplasma contamination. VIII. Characterize cell lines for expression of molecular makers that confirm the tumor-type of the cell line and the immortal nature of the cells (telomerase) and the expression of molecular markers that may correlate with drug resistance.
OUTLINE: This is a multicenter study.
Specimens are stratified according to disease (acute lymphoblastic leukemia vs acute myeloid leukemia vs lymphoma vs osteogenic sarcoma vs Ewing family of tumors vs rhabdomyosarcoma vs primitive neuroectodermal tumor vs glioma vs astrocytoma vs rhabdoid tumors vs hepatoblastoma vs retinoblastoma vs Wilms tumor vs germ cell tumors vs other diagnoses).
Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following:
NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens
EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5
RETINOBLASTOMA: interphotoreceptor retinoid-binding protein
ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype
ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1
ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry.
No results of these tests are provided to the patient, the patient's physician, or the patient's medical records.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 213
-
All malignant tissues from childhood cancers allowed including the following:
-
Brain tumors (all types)
- Tissue should be submitted to CNS Committee Resource labs to be forwarded for this study, unless instructed otherwise on the COG web site
-
Ewing family of tumors
-
Rhabdomyosarcomas
-
Other soft tissue sarcomas
-
Osteogenic sarcomas
-
Rhabdoid tumors
-
Neuroblastomas
- Viable material for cell culture for neuroblastoma is collected via COG-ANBL00B1 and should not be submitted via this study unless the patient cannot be enrolled on COG-ANBL00B1*
-
Retinoblastomas
-
Anaplastic Wilms tumor
-
Germ cell tumors
-
Leukemias/lymphomas
-
Acute myeloid leukemia (AML)
- Blood samples and bone marrow samples from patients at second relapse and beyond may be submitted for this study
- Bone marrow samples at diagnosis or first relapse must be submitted to an AML resource lab and will be forwarded for this study at the discretion of the AML Committee
-
Acute lymphoblastic leukemia (ALL)
- Blood samples may be submitted directly to this study
- Bone marrow samples must be submitted to an ALL resource lab and will be forwarded for this study at the discretion of the ALL Committee
-
-
-
Enrolled on a COG therapeutic, biology, or tissue banking protocol that allows collection of tissue for research and submission to a COG-designated resource laboratory
- Participation in this protocol is not permitted until after tissue requirements for any active COG disease-specific therapeutic, biology, or banking protocols have been satisfied
- Material may only be submitted for this protocol if tissue is available in excess of that required for satisfying active disease-specific therapeutic and biological protocols
-
Patients with diagnosis pending are eligible
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Ancillary-Correlative (tissue sample collection) Laboratory Biomarker Analysis Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following: NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5 RETINOBLASTOMA: interphotoreceptor retinoid-binding protein ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1 ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry Ancillary-Correlative (tissue sample collection) Cytology Specimen Collection Procedure Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following: NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5 RETINOBLASTOMA: interphotoreceptor retinoid-binding protein ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1 ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry
- Primary Outcome Measures
Name Time Method Establishment of continuous cell lines, under carefully controlled conditions, from pediatric patients with cancer Up to 14 years Characterization of cell lines for the ability for sustained growth in tissue culture and/or as mouse xenografts Up to 14 years Characterization of cell lines for mycoplasma contamination Up to 14 years Creation of a bank of cell lines and generation of sufficient vials of cryopreserved cells for distribution to investigators with approved COG biology protocols Up to 14 years Characterization of cell lines for expression of molecular makers that confirm the tumor-type of the cell line and the immortal nature of the cells (telomerase) and the expression of molecular markers that may correlate with drug resistance Up to 14 years Establishment and banking of cell lines and/or xenografts from pediatric patients with cancer Up to 14 years Establishment of transplantable xenografts in immunocompromised mice from tumor cells that are difficult to establish as continuous cell lines in vitro Up to 14 years Characterization of cell lines from childhood cancers with respect to DNA PCR molecular HLA profile as a "fingerprint" of original cell line identity Up to 14 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (68)
Children's Hospital Medical Center of Akron
🇺🇸Akron, Ohio, United States
Children's Hospital Los Angeles
🇺🇸Los Angeles, California, United States
University of Illinois
🇺🇸Chicago, Illinois, United States
Massachusetts General Hospital Cancer Center
🇺🇸Boston, Massachusetts, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
University Medical Center of Southern Nevada
🇺🇸Las Vegas, Nevada, United States
Nevada Cancer Research Foundation CCOP
🇺🇸Las Vegas, Nevada, United States
Sunrise Hospital and Medical Center
🇺🇸Las Vegas, Nevada, United States
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
🇺🇸Las Vegas, Nevada, United States
Saskatoon Cancer Centre
🇨🇦Saskatoon, Saskatchewan, Canada
University of Texas Health Science Center at San Antonio
🇺🇸San Antonio, Texas, United States
Wayne State University/Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
University of Oklahoma Health Sciences Center
🇺🇸Oklahoma City, Oklahoma, United States
Children's Hospital of Alabama
🇺🇸Birmingham, Alabama, United States
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
🇺🇸Denver, Colorado, United States
Children's Hospital and Medical Center of Omaha
🇺🇸Omaha, Nebraska, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Tampa General Hospital
🇺🇸Tampa, Florida, United States
Saint Joseph's Hospital/Children's Hospital-Tampa
🇺🇸Tampa, Florida, United States
University of Alabama at Birmingham Cancer Center
🇺🇸Birmingham, Alabama, United States
Saint Luke's Mountain States Tumor Institute
🇺🇸Boise, Idaho, United States
Wake Forest University Health Sciences
🇺🇸Winston-Salem, North Carolina, United States
Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
Albany Medical Center
🇺🇸Albany, New York, United States
Tulane University Health Sciences Center
🇺🇸New Orleans, Louisiana, United States
Ochsner Medical Center Jefferson
🇺🇸New Orleans, Louisiana, United States
Children's Mercy Hospitals and Clinics
🇺🇸Kansas City, Missouri, United States
Driscoll Children's Hospital
🇺🇸Corpus Christi, Texas, United States
UMC Cancer Center / UMC Health System
🇺🇸Lubbock, Texas, United States
Rainbow Babies and Childrens Hospital
🇺🇸Cleveland, Ohio, United States
Children's Hospital of Pittsburgh of UPMC
🇺🇸Pittsburgh, Pennsylvania, United States
Saint Jude Midwest Affiliate
🇺🇸Peoria, Illinois, United States
University of Kentucky/Markey Cancer Center
🇺🇸Lexington, Kentucky, United States
City of Hope Comprehensive Cancer Center
🇺🇸Duarte, California, United States
Covenant Children's Hospital
🇺🇸Lubbock, Texas, United States
Johns Hopkins All Children's Hospital
🇺🇸Saint Petersburg, Florida, United States
Bronson Methodist Hospital
🇺🇸Kalamazoo, Michigan, United States
Summerlin Hospital Medical Center
🇺🇸Las Vegas, Nevada, United States
Columbia Regional
🇺🇸Columbia, Missouri, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Norton Children's Hospital
🇺🇸Louisville, Kentucky, United States
Montefiore Medical Center - Moses Campus
🇺🇸Bronx, New York, United States
Lee Memorial Health System
🇺🇸Fort Myers, Florida, United States
Golisano Children's Hospital of Southwest Florida
🇺🇸Fort Myers, Florida, United States
Kalamazoo Center for Medical Studies
🇺🇸Kalamazoo, Michigan, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
🇺🇸New York, New York, United States
Overlook Hospital
🇺🇸Summit, New Jersey, United States
Miller Children's and Women's Hospital Long Beach
🇺🇸Long Beach, California, United States
Arkansas Children's Hospital
🇺🇸Little Rock, Arkansas, United States
Carolinas Medical Center/Levine Cancer Institute
🇺🇸Charlotte, North Carolina, United States
Dayton Children's Hospital
🇺🇸Dayton, Ohio, United States
Children's Hospital and Research Center at Oakland
🇺🇸Oakland, California, United States
Southern Illinois University School of Medicine
🇺🇸Springfield, Illinois, United States
Morristown Medical Center
🇺🇸Morristown, New Jersey, United States
Kaiser Permanente Downey Medical Center
🇺🇸Downey, California, United States
Saint Mary's Hospital
🇺🇸West Palm Beach, Florida, United States
Centre Hospitalier Universitaire Sainte-Justine
🇨🇦Montreal, Quebec, Canada
East Tennessee Childrens Hospital
🇺🇸Knoxville, Tennessee, United States
Connecticut Children's Medical Center
🇺🇸Hartford, Connecticut, United States
University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States
Sinai Hospital of Baltimore
🇺🇸Baltimore, Maryland, United States
British Columbia Children's Hospital
🇨🇦Vancouver, British Columbia, Canada
MedStar Georgetown University Hospital
🇺🇸Washington, District of Columbia, United States
BI-LO Charities Children's Cancer Center
🇺🇸Greenville, South Carolina, United States
Texas Tech University Health Sciences Center-Amarillo
🇺🇸Amarillo, Texas, United States
Methodist Children's Hospital of South Texas
🇺🇸San Antonio, Texas, United States
Madigan Army Medical Center
🇺🇸Tacoma, Washington, United States
Greenville Cancer Treatment Center
🇺🇸Greenville, South Carolina, United States